Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 12:10:2147-2154.
doi: 10.2147/OTT.S128451. eCollection 2017.

Soluble cytotoxic T-lymphocyte antigen 4: a favorable predictor in malignant tumors after therapy

Qiqi Liu  1 , Pingping Hu  1 , Guodong Deng  1 , Jingxin Zhang  2 , Ning Liang  1 , Jian Xie  1 , Lili Qiao  3 , Hui Luo  4 , Jiandong Zhang  1
Affiliations

Soluble cytotoxic T-lymphocyte antigen 4: a favorable predictor in malignant tumors after therapy

Qiqi Liu et al. Onco Targets Ther. .

Abstract

Purpose: Soluble cytotoxic T-lymphocyte antigen 4 (sCTLA-4), one of the isoforms of CTLA-4, was discovered to be critical in downregulating the negative signal of CTLA-4 in T-cell responses. Contrary to the classical immunosuppressive effect of CTLA-4, its immunoregulatory function might be complicated. However, the clinical significance of sCTLA-4 to immune regulation and the variation in cancer therapy have not been elucidated. We postulated that the level of sCTLA-4 might affect the outcome of cancer prognosis.

Patients and methods: Serum concentrations of sCTLA-4 before and after therapy in 141 locally advanced and advanced cancer patients were measured and survival analyses was performed. Hazard ratio and 95% confidence interval for overall survival (OS) were calculated. Cutoffs were determined by median across the sCTLA-4 level of entire patients.

Results: High expression of sCTLA-4 after therapy indicated significant longer OS and progression-free survival (PFS) (all P<0.01). Among all subgroups, sCTLA-4 levels after therapies were found to be significantly higher than that of 1 day before, which was also negatively correlated with tumor node metastasis stage and lymph node metastasis (all P<0.05). Multivariate analysis revealed that sCTLA-4 level was a strong independent prognostic factor for OS and PFS (all P<0.05).

Conclusion: Our data demonstrated the favorable prognostic significance of sCTLA-4 and may lead to the development of new immunotherapy options for cancer patients.

Keywords: cancer prognosis; cancer therapy; immunotherapy; soluble cytotoxic T-lymphocyte antigen 4; survival.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Level of sCTLA-4 in all 4 groups. Notes: Compared with the level of sCTLA-4 1 day before therapies, sCTLA-4 levels during therapies were significantly higher among all these 4 subgroups including the (A) RT, (B) chemotherapy, (C) CRT, and (D) whole patient group (all P<0.05). Abbreviations: CRT, chemoradiotherapy; RT, radiotherapy; sCTLA-4, soluble cytotoxic T-lymphocyte antigen 4.
Figure 2
Figure 2
Survival curves for OS in all 4 groups. Notes: Survival analysis was according to sCTLA-4 levels during therapy, with green indicating upregulated sCTLA-4 levels and blue denoting downregulated sCTLA-4 levels. Patients in the (A) RT, (B) chemotherapy, (C) CRT, and (D) whole patient groups with upregulated sCTLA-4 levels had longer OS than patients with downregulated sCTLA-4 levels (all P<0.05, log-rank test). Abbreviations: CRT, chemoradiotherapy; OS, overall survival; RT, radiotherapy; sCTLA-4, soluble cytotoxic T-lymphocyte antigen 4.
Figure 3
Figure 3
Survival curves for PFS in all 4 groups. Notes: Survival analysis was according to sCTLA-4 levels during therapy, with green indicating upregulated sCTLA-4 levels and blue denoting downregulated sCTLA-4 levels. Patients in the (A) RT, (B) chemotherapy, (C) CRT, and (D) whole patient groups with upregulated sCTLA-4 levels had longer PFS than patients with downregulated sCTLA-4 levels (all P<0.05, log-rank test). Abbreviations: CRT, chemoradiotherapy; PFS, progression-free survival; RT, radiotherapy; sCTLA-4, soluble cytotoxic T-lymphocyte antigen 4.
See this image and copyright information in PMC

References

    1. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–489. - PMC - PubMed
    1. Koch MA, Thomas KR, Perdue NR, Smigiel KS, Srivastava S, Campbell DJ. T-bet (+) Treg cells undergo abortive Th1 cell differentiation due to impaired expression of IL-12 receptor β2. Immunity. 2012;37(3):501–510. - PMC - PubMed
    1. Yu HM, Yang JL, Jiao SC, Wang JD, Li Y. TGF-beta1 precursor and CD8 are potential prognostic and predictive markers in operated breast cancer. J Huazhong Univ Sci Technolog Med Sci. 2014;34(1):51–58. - PubMed
    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. - PMC - PubMed
    1. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. - PMC - PubMed

LinkOut - more resources